This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Lupus	MAP kinase kinase kinase 3 (MAP4K3; GLK)	<p>Patient sample and mouse studies suggest inhibiting GLK could help treat autoimmune diseases such as lupus. In a mouse model of experimental autoimmune encephalomyelitis, GLK-deficient animals had lower T cell-mediated immune responses and less disease severity than wild-type mice. Peripheral blood leukocyte samples from 49 systemic lupus erythematosus (SLE) patients had a higher percentage GLK-expressing T cells than samples from 35 healthy controls. Next steps include developing GLK inhibitors.</p> <p>SciBX 4(42); doi:10.1038/scibx.2011.1169 Published online Oct. 27, 2011</p>	Provisional U.S. patent application filed; available for licensing	<p>Chuang, H.-C. <i>et al. Nat. Immunol.</i>; published online Oct. 9, 2011; doi:10.1038/ni.2121</p> <p>Contact: Tse-Hua Tan, National Health Research Institutes, Zhunan, Taiwan e-mail: ttan@nhri.org.tw</p>